Hormone therapy in the WHI era
The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and...
Gespeichert in:
| Veröffentlicht in: | Australian & New Zealand journal of obstetrics & gynaecology 2006-04, Vol.46 (2), p.84-91 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 2 |
| container_start_page | 84 |
| container_title | Australian & New Zealand journal of obstetrics & gynaecology |
| container_volume | 46 |
| creator | BURGER, Henry G. |
| description | The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and the subsequent publications leads to the conclusion that the widespread fear of hormone therapy that was generated was not supported by the facts. WHI was not designed to be, nor can it be, interpreted as a randomised controlled trial of menopausal hormone therapy – rather, it was a trial of chronic disease prevention, particularly aimed at the possible cardiovascular benefits of a specific combination hormone therapy in postmenopausal women. The results, which were consistent with existing data, did not and do not warrant any major change in the previously established guidelines for the use of hormone therapy. Tibolone has emerged as an alternative treatment for menopausal symptoms, but its long‐term benefits and risks have yet to be documented. |
| doi_str_mv | 10.1111/j.1479-828X.2006.00533.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67908061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67908061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4043-eec8af65a76a79b373443041a19dbfa528aaec817046ea38f08d8e1272d2550e3</originalsourceid><addsrcrecordid>eNqNkM9PwjAUxxujEUT_BbKTt83X9ecSL4QoYIgc0MCtKVsXhxvDFiL893aO4NVe-tL3_by-fBAKMETYn4d1hKlIQhnLZRQD8AiAERIdLlD33LhEXQCgoeScd9CNc2sAnDBMr1EHc04kxKKL-uPaVvXGBLsPY_X2GBSbpgwW40ngH27RVa5LZ-5Odw-9Pz-9DcfhdDaaDAfTMKVASWhMKnXOmRZci2RFBKGUAMUaJ9kq1yyWWvsIFkC50UTmIDNpcCziLGYMDOmh-3bu1tZfe-N2qipcaspSb0y9d4qLBCRw7IOyDaa2ds6aXG1tUWl7VBhU40atVaNANQpU40b9ulEHj_ZPf-xXlcn-wJMMH3hsA99FaY7_HqwGLzNfeDxs8cLtzOGMa_vp1yeCqcXrSBEMc7accjUnPwp5fws</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67908061</pqid></control><display><type>article</type><title>Hormone therapy in the WHI era</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>BURGER, Henry G.</creator><creatorcontrib>BURGER, Henry G.</creatorcontrib><description>The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and the subsequent publications leads to the conclusion that the widespread fear of hormone therapy that was generated was not supported by the facts. WHI was not designed to be, nor can it be, interpreted as a randomised controlled trial of menopausal hormone therapy – rather, it was a trial of chronic disease prevention, particularly aimed at the possible cardiovascular benefits of a specific combination hormone therapy in postmenopausal women. The results, which were consistent with existing data, did not and do not warrant any major change in the previously established guidelines for the use of hormone therapy. Tibolone has emerged as an alternative treatment for menopausal symptoms, but its long‐term benefits and risks have yet to be documented.</description><identifier>ISSN: 0004-8666</identifier><identifier>EISSN: 1479-828X</identifier><identifier>DOI: 10.1111/j.1479-828X.2006.00533.x</identifier><identifier>PMID: 16638027</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>Aged ; breast cancer ; cardiovascular disease ; Cardiovascular Diseases - prevention & control ; Estrogen Replacement Therapy - standards ; Estrogen Replacement Therapy - trends ; Female ; Forecasting ; hormone therapy ; Humans ; menopause ; Menopause - drug effects ; Menopause - physiology ; Middle Aged ; Norpregnenes - therapeutic use ; osteoporosis ; Osteoporosis, Postmenopausal - prevention & control ; Randomized Controlled Trials as Topic ; Risk Assessment ; Thromboembolism - prevention & control ; venous thromboembolism ; Victoria ; Women's Health</subject><ispartof>Australian & New Zealand journal of obstetrics & gynaecology, 2006-04, Vol.46 (2), p.84-91</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4043-eec8af65a76a79b373443041a19dbfa528aaec817046ea38f08d8e1272d2550e3</citedby><cites>FETCH-LOGICAL-c4043-eec8af65a76a79b373443041a19dbfa528aaec817046ea38f08d8e1272d2550e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1479-828X.2006.00533.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1479-828X.2006.00533.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>313,314,776,780,788,1411,27901,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16638027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BURGER, Henry G.</creatorcontrib><title>Hormone therapy in the WHI era</title><title>Australian & New Zealand journal of obstetrics & gynaecology</title><addtitle>Aust N Z J Obstet Gynaecol</addtitle><description>The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and the subsequent publications leads to the conclusion that the widespread fear of hormone therapy that was generated was not supported by the facts. WHI was not designed to be, nor can it be, interpreted as a randomised controlled trial of menopausal hormone therapy – rather, it was a trial of chronic disease prevention, particularly aimed at the possible cardiovascular benefits of a specific combination hormone therapy in postmenopausal women. The results, which were consistent with existing data, did not and do not warrant any major change in the previously established guidelines for the use of hormone therapy. Tibolone has emerged as an alternative treatment for menopausal symptoms, but its long‐term benefits and risks have yet to be documented.</description><subject>Aged</subject><subject>breast cancer</subject><subject>cardiovascular disease</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Estrogen Replacement Therapy - standards</subject><subject>Estrogen Replacement Therapy - trends</subject><subject>Female</subject><subject>Forecasting</subject><subject>hormone therapy</subject><subject>Humans</subject><subject>menopause</subject><subject>Menopause - drug effects</subject><subject>Menopause - physiology</subject><subject>Middle Aged</subject><subject>Norpregnenes - therapeutic use</subject><subject>osteoporosis</subject><subject>Osteoporosis, Postmenopausal - prevention & control</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Thromboembolism - prevention & control</subject><subject>venous thromboembolism</subject><subject>Victoria</subject><subject>Women's Health</subject><issn>0004-8666</issn><issn>1479-828X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM9PwjAUxxujEUT_BbKTt83X9ecSL4QoYIgc0MCtKVsXhxvDFiL893aO4NVe-tL3_by-fBAKMETYn4d1hKlIQhnLZRQD8AiAERIdLlD33LhEXQCgoeScd9CNc2sAnDBMr1EHc04kxKKL-uPaVvXGBLsPY_X2GBSbpgwW40ngH27RVa5LZ-5Odw-9Pz-9DcfhdDaaDAfTMKVASWhMKnXOmRZci2RFBKGUAMUaJ9kq1yyWWvsIFkC50UTmIDNpcCziLGYMDOmh-3bu1tZfe-N2qipcaspSb0y9d4qLBCRw7IOyDaa2ds6aXG1tUWl7VBhU40atVaNANQpU40b9ulEHj_ZPf-xXlcn-wJMMH3hsA99FaY7_HqwGLzNfeDxs8cLtzOGMa_vp1yeCqcXrSBEMc7accjUnPwp5fws</recordid><startdate>200604</startdate><enddate>200604</enddate><creator>BURGER, Henry G.</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200604</creationdate><title>Hormone therapy in the WHI era</title><author>BURGER, Henry G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4043-eec8af65a76a79b373443041a19dbfa528aaec817046ea38f08d8e1272d2550e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>breast cancer</topic><topic>cardiovascular disease</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Estrogen Replacement Therapy - standards</topic><topic>Estrogen Replacement Therapy - trends</topic><topic>Female</topic><topic>Forecasting</topic><topic>hormone therapy</topic><topic>Humans</topic><topic>menopause</topic><topic>Menopause - drug effects</topic><topic>Menopause - physiology</topic><topic>Middle Aged</topic><topic>Norpregnenes - therapeutic use</topic><topic>osteoporosis</topic><topic>Osteoporosis, Postmenopausal - prevention & control</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Thromboembolism - prevention & control</topic><topic>venous thromboembolism</topic><topic>Victoria</topic><topic>Women's Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BURGER, Henry G.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Australian & New Zealand journal of obstetrics & gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BURGER, Henry G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hormone therapy in the WHI era</atitle><jtitle>Australian & New Zealand journal of obstetrics & gynaecology</jtitle><addtitle>Aust N Z J Obstet Gynaecol</addtitle><date>2006-04</date><risdate>2006</risdate><volume>46</volume><issue>2</issue><spage>84</spage><epage>91</epage><pages>84-91</pages><issn>0004-8666</issn><eissn>1479-828X</eissn><abstract>The announcement in July 2002 in the media of the results of the combined continuous hormone treatment arm of the Women's Health Initiative (WHI) had a profound effect on perceptions about hormone therapy among the lay public and the medical profession. Careful scrutiny of the announcement and the subsequent publications leads to the conclusion that the widespread fear of hormone therapy that was generated was not supported by the facts. WHI was not designed to be, nor can it be, interpreted as a randomised controlled trial of menopausal hormone therapy – rather, it was a trial of chronic disease prevention, particularly aimed at the possible cardiovascular benefits of a specific combination hormone therapy in postmenopausal women. The results, which were consistent with existing data, did not and do not warrant any major change in the previously established guidelines for the use of hormone therapy. Tibolone has emerged as an alternative treatment for menopausal symptoms, but its long‐term benefits and risks have yet to be documented.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>16638027</pmid><doi>10.1111/j.1479-828X.2006.00533.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-8666 |
| ispartof | Australian & New Zealand journal of obstetrics & gynaecology, 2006-04, Vol.46 (2), p.84-91 |
| issn | 0004-8666 1479-828X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67908061 |
| source | MEDLINE; Wiley Online Library |
| subjects | Aged breast cancer cardiovascular disease Cardiovascular Diseases - prevention & control Estrogen Replacement Therapy - standards Estrogen Replacement Therapy - trends Female Forecasting hormone therapy Humans menopause Menopause - drug effects Menopause - physiology Middle Aged Norpregnenes - therapeutic use osteoporosis Osteoporosis, Postmenopausal - prevention & control Randomized Controlled Trials as Topic Risk Assessment Thromboembolism - prevention & control venous thromboembolism Victoria Women's Health |
| title | Hormone therapy in the WHI era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A49%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hormone%20therapy%20in%20the%20WHI%20era&rft.jtitle=Australian%20&%20New%20Zealand%20journal%20of%20obstetrics%20&%20gynaecology&rft.au=BURGER,%20Henry%20G.&rft.date=2006-04&rft.volume=46&rft.issue=2&rft.spage=84&rft.epage=91&rft.pages=84-91&rft.issn=0004-8666&rft.eissn=1479-828X&rft_id=info:doi/10.1111/j.1479-828X.2006.00533.x&rft_dat=%3Cproquest_cross%3E67908061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67908061&rft_id=info:pmid/16638027&rfr_iscdi=true |